Journal article
Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET
N Okamura, S Furumoto, MT Fodero-Tavoletti, RS Mulligan, R Harada, P Yates, S Pejoska, Y Kudo, CL Masters, K Yanai, CC Rowe, VL Villemagne
Brain | OXFORD UNIV PRESS | Published : 2014
DOI: 10.1093/brain/awu064
Abstract
Non-invasive imaging of tau pathology in the living brain would be useful for accurately diagnosing Alzheimer's disease, tracking disease progression, and evaluating the treatment efficacy of disease-specific therapeutics. In this study, we evaluated the clinical usefulness of a novel tau-imaging positron emission tomography tracer 18F-THK5105 in 16 human subjects including eight patients with Alzheimer's disease (three male and five females, 66-82 years) and eight healthy elderly controls (three male and five females, 63-76 years). All participants underwent neuropsychological examination and 3D magnetic resonance imaging, as well as both 18F-THK5105 and 11C-Pittsburgh compound B positron e..
View full abstractGrants
Awarded by Japan Society for the Promotion of Science
Funding Acknowledgements
This study was supported by the research fund from GE Healthcare, the SEI (Sumitomo Electric Industries, Ltd) Group CSR Foundation, NHMRC grant 1044361 and NIRG grant from the Alzheimer's Association, the Industrial Technology Research Grant Program of the New Energy and Industrial Technology Development Organization (NEDO) in Japan (09E51025a), Health and Labor Sciences Research Grants from the Ministry of Health, Labor, and Welfare of Japan, Grant-in-Aid for Scientific Research (B) (23390297) and "Japan Advanced Molecular Imaging Program (J-AMP)" of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.